Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.

Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan VD, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS, Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE.

Hum Vaccin Immunother. 2012 May;8(5):630-8. doi: 10.4161/hv.19454. Epub 2012 May 1.

PMID:
22634443
[PubMed - indexed for MEDLINE]
2.

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.

Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026.

PMID:
22520138
[PubMed - indexed for MEDLINE]
3.

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.

Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096.

PMID:
19943789
[PubMed - indexed for MEDLINE]
4.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M.

Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9.

PMID:
21907749
[PubMed - indexed for MEDLINE]
5.
6.

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.

Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, Verani-Ketter N, Erb S, Smith CM, Belshe RB, Wagner LJ, McElrath MJ, Schwartz DH, Fast P.

AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1163-77.

PMID:
9310283
[PubMed - indexed for MEDLINE]
7.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.

Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

PMID:
24560541
[PubMed - indexed for MEDLINE]
8.

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.

Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):873-80. doi: 10.1089/aid.2008.0292.

PMID:
18544020
[PubMed - indexed for MEDLINE]
9.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.

PMID:
21816199
[PubMed - indexed for MEDLINE]
10.

Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa.

Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, Nakyanzi T, Wang L, Fowler MG, Emel L, Ou SS, Baglyos L, Gurunathan S, Zwerski S, Jackson JB, Guay L.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):1-8. doi: 10.1097/QAI.0b013e31827f1c2d.

PMID:
23221981
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.

[No authors listed]

AIDS. 2001 May 4;15(7):W27-44.

PMID:
11399975
[PubMed - indexed for MEDLINE]
12.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group.

J Infect Dis. 2006 Dec 15;194(12):1661-71. Epub 2006 Nov 3.

PMID:
17109337
[PubMed - indexed for MEDLINE]
Free Article
13.

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.

LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.

Clin Ther. 2007 Aug;29(8):1579-90; discussion 1577-8.

PMID:
17919541
[PubMed - indexed for MEDLINE]
14.

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network.

Vaccine. 2003 Jun 20;21(21-22):2933-47.

PMID:
12798637
[PubMed - indexed for MEDLINE]
15.

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.

Durier C, Launay O, Meiffrédy V, Saïdi Y, Salmon D, Lévy Y, Guillet JG, Pialoux G, Aboulker JP.

AIDS. 2006 Apr 24;20(7):1039-49.

PMID:
16603857
[PubMed - indexed for MEDLINE]
16.

Trial-related discrimination in HIV vaccine clinical trials.

Allen M, Israel H, Rybczyk K, Pugliese MA, Loughran K, Wagner L, Erb S.

AIDS Res Hum Retroviruses. 2001 May 20;17(8):667-74.

PMID:
11429107
[PubMed - indexed for MEDLINE]
17.

Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.

Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS.

Public Health Rep. 2005 Sep-Oct;120(5):543-8.

PMID:
16224987
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.

Jenkins RA, Chinaworapong S, Morgan PA, Ruangyuttikarn C, Sontirat A, Chiu J, Michael RA, Nitayaphan S, Khamboonruang C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1;18(2):171-7.

PMID:
9637582
[PubMed - indexed for MEDLINE]
19.

The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.

Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker LG.

Int J STD AIDS. 2014 Apr;25(5):332-40. doi: 10.1177/0956462413506892. Epub 2013 Oct 8.

PMID:
24104693
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):222-30.

PMID:
17693888
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk